for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Kaibao Pharmaceutical CO.,LTD.

300039.SZ

Latest Trade

4.04CNY

Change

-0.05(-1.22%)

Volume

4,401,316

Today's Range

4.02

 - 

4.12

52 Week Range

3.70

 - 

7.13

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.09
Open
4.11
Volume
4,401,316
3M AVG Volume
142.25
Today's High
4.12
Today's Low
4.02
52 Week High
7.13
52 Week Low
3.70
Shares Out (MIL)
1,046.00
Market Cap (MIL)
4,194.46
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2020 Shanghai Kaibao Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Shanghai Kaibao Pharmaceutical Plans Share Buyback Worth Between 100 Mln Yuan And 200 Mln Yuan

Shanghai Kaibao Pharmaceutical sees H1 2018 net profit down 0 pct to 10 pct

Shanghai Kaibao Pharmaceutical to pay annual cash div as 1 yuan per 10 shares for FY 2017

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Kaibao Pharmaceutical CO.,LTD.

Shanghai Kaibao Pharmaceutical CO.,Ltd. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent drugs. The Company's main product is Tanreqing injection, which is used for treatment of upper respiratory tract infections, such as cold and pneumonia. The Company's products include injections, tablets, capsules, granules, vinum and pills, among others. The Company distributes its products in domestic markets.

Industry

Major Drugs

Contact Info

No. 88

Chengpu Road

Industrial Comprehensive Development Zne

SHANGHAI, SHA

201401

China

+86.21.37572069

http://www.xykb.com/

Executive Leadership

Jingwei Mu

Chairman of the Board

Yuqin Zhang

Chief Financial Officer

Guoming Wang

General Manager

Shaoyong Liu

Deputy General Manager, Director

Dongsheng Xue

Deputy General Manager, Director

Key Stats

Price To Earnings (TTM)
27.99
Price To Sales (TTM)
4.18
Price To Book (MRQ)
1.63
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.39
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
5.72
Return on Equity (TTM)
5.26

Latest News

Latest News

アングル:中国が野生動物の食用利用禁止へ、「医療目的」は例外か

22日に開幕する中国全国人民代表大会(全人代、国会に相当)は、野生動物の食用利用を禁止するため、法制化を進める見通しだが、毛皮の取引や医薬品としての利用は今後も続くとみられる。

China legislators take on wildlife trade, but traditional medicine likely to be exempt

As China's parliament prepares new laws to ban the trade and consumption of wildlife, local action plans published this week suggest the country's fur trade and lucrative traditional medicine sectors will continue as usual.

Exclusive: Unilever, 3M on list of firms eligible for China loans to ease coronavirus crisis - sources

Shanghai has compiled a list of firms, including local units of multi-nationals Unilever PLC <ULVR.L> and 3M Co <MMM.N>, as eligible for millions of dollars in subsidized loans to ease any blow from the coronavirus outbreak, according to bankers and documents seen by Reuters...

BRIEF-Shanghai Kaibao Pharmaceutical to pay annual cash div as 1 yuan per 10 shares for FY 2017

* Says it plans to pay annual cash dividend as 1 yuan(pre-tax) per 10 shares as FY 2017 div payment

BRIEF-Shanghai Kaibao Pharmaceutical Sees Q1 Net Profit Up 5-15 Percent Y/Y

* SAYS IT SEES Q1 NET PROFIT UP 5-15 PERCENT Y/Y AT 95.2-104.3 MILLION YUAN ($15.15-$16.60 million) Source text in Chinese: https://bit.ly/2uDFSfy Further company coverage: ($1 = 6.2835 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF- Shanghai Kaibao Pharmaceutical obtains high-tech enterprise recognition and to enjoy tax preference

* Says it was recognized as high-tech enterprise again, and to enjoy a tax preference of 15 percent for three years

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up